These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 34127329)
1. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma. Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Hayami S; Ueno M; Yamaue H Eur J Surg Oncol; 2021 Oct; 47(10):2586-2594. PubMed ID: 34127329 [TBL] [Abstract][Full Text] [Related]
2. Left posterior approach pancreaticoduodenectomy with total mesopancreas excision and circumferential lymphadenectomy around the superior mesenteric artery for pancreatic head carcinoma. Aimoto T; Mizutani S; Kawano Y; Matsushita A; Yamashita N; Suzuki H; Uchida E J Nippon Med Sch; 2013; 80(6):438-45. PubMed ID: 24419715 [TBL] [Abstract][Full Text] [Related]
3. Correspondence regarding "Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma". Vasavada B Eur J Surg Oncol; 2022 Jan; 48(1):302. PubMed ID: 34802861 [No Abstract] [Full Text] [Related]
4. Reply to: Correspondence reading "Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma". Hirono S; Yamaue H Eur J Surg Oncol; 2022 Jan; 48(1):300-301. PubMed ID: 34819244 [No Abstract] [Full Text] [Related]
5. Para-aortic lymph nodes and ductal adenocarcinoma of the pancreas: Distant neighbors? Safi SA; Rehders A; Haeberle L; Fung S; Lehwald N; Esposito I; Ziayee F; Krieg A; Knoefel WT; Fluegen G Surgery; 2021 Dec; 170(6):1807-1814. PubMed ID: 34392977 [TBL] [Abstract][Full Text] [Related]
6. Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015). Yamada D; Kobayashi S; Takahashi H; Iwagami Y; Akita H; Asukai K; Shimizu J; Yamada T; Tanemura M; Yokoyama S; Tsujie M; Asaoka T; Takeda Y; Morimoto O; Tomokuni A; Doki Y; Eguchi H Ann Surg Oncol; 2024 Jul; 31(7):4621-4633. PubMed ID: 38546797 [TBL] [Abstract][Full Text] [Related]
7. Complete Lymphadenectomy Around the Entire Superior Mesenteric Artery Improves Survival in Artery-First Approach Pancreatoduodenectomy for T3 Pancreatic Ductal Adenocarcinoma. Kobayashi S; Otsubo T; Nakano H; Koizumi S; Nakahara K World J Surg; 2021 Mar; 45(3):857-864. PubMed ID: 33174091 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma. Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Matsunaga Y; Shiihara M; Yamamoto M Pancreatology; 2021 Apr; 21(3):581-588. PubMed ID: 33579600 [TBL] [Abstract][Full Text] [Related]
9. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma. Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050 [TBL] [Abstract][Full Text] [Related]
10. Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety. Inoue Y; Saiura A; Oba A; Kawakatsu S; Ono Y; Sato T; Mise Y; Ishizawa T; Takahashi Y; Ito H J Gastrointest Surg; 2019 Jul; 23(7):1373-1383. PubMed ID: 30306451 [TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma. Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534 [TBL] [Abstract][Full Text] [Related]
12. [The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy]. Imamura T; Ikoma H; Morimura R; Hatakeyama T; Kosuga T; Konishi H; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Otsuji E Gan To Kagaku Ryoho; 2015 Nov; 42(12):2379-81. PubMed ID: 26805370 [TBL] [Abstract][Full Text] [Related]
13. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy. Yamada D; Eguchi H; Iwagami Y; Asaoka T; Noda T; Kawamoto K; Gotoh K; Kobayashi S; Mori M; Doki Y Surg Today; 2018 Oct; 48(10):952-962. PubMed ID: 29770847 [TBL] [Abstract][Full Text] [Related]
14. Long-term survival after resection of pancreatic ductal adenocarcinoma with para-aortic lymph node metastasis: case report. Masui T; Kubota T; Aoki K; Nakanishi Y; Miyamoto T; Nagata J; Morino K; Fukugaki A; Takamura M; Sugimoto S; Onuma H; Tokuka A World J Surg Oncol; 2013 Aug; 11(1):195. PubMed ID: 23945441 [TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcome of Patients with Postoperative Refractory Diarrhea After Tailored Nerve Plexus Dissection Around the Major Visceral Arteries During Pancreatoduodenectomy for Pancreatic Cancer. Kuroki N; Ono Y; Sato T; Inoue Y; Oba A; Ito H; Mise Y; Saiura A; Takahashi Y World J Surg; 2022 May; 46(5):1172-1182. PubMed ID: 35119513 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Lymph Node Metastasis and Micrometastasis Along the Left Side of Superior Mesenteric Artery in Pancreatic Head Cancer. Okada K; Murakami Y; Kondo N; Uemura K; Nakagawa N; Seo S; Takahashi S; Sueda T J Gastrointest Surg; 2019 Oct; 23(10):2100-2109. PubMed ID: 31410820 [TBL] [Abstract][Full Text] [Related]
17. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomized controlled trial of 354 patients with pancreatic ductal adenocarcinoma. Hirono S; Kawai M; Okada KI; Fujii T; Sho M; Satoi S; Amano R; Eguchi H; Mataki Y; Nakamura M; Matsumoto I; Baba H; Tani M; Kawabata Y; Nagakawa Y; Yamada S; Murakami Y; Shimokawa T; Yamaue H Trials; 2018 Nov; 19(1):613. PubMed ID: 30409152 [TBL] [Abstract][Full Text] [Related]
18. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. Katz MH; Wang H; Balachandran A; Bhosale P; Crane CH; Wang X; Pisters PW; Lee JE; Vauthey JN; Abdalla EK; Wolff R; Abbruzzese J; Varadhachary G; Chopin-Laly X; Charnsangavej C; Fleming JB J Gastrointest Surg; 2012 Jan; 16(1):68-78; discussion 78-9. PubMed ID: 22065318 [TBL] [Abstract][Full Text] [Related]
19. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Jones RP; Psarelli EE; Jackson R; Ghaneh P; Halloran CM; Palmer DH; Campbell F; Valle JW; Faluyi O; O'Reilly DA; Cunningham D; Wadsley J; Darby S; Meyer T; Gillmore R; Anthoney A; Lind P; Glimelius B; Falk S; Izbicki JR; Middleton GW; Cummins S; Ross PJ; Wasan H; McDonald A; Crosby T; Ting Y; Patel K; Sherriff D; Soomal R; Borg D; Sothi S; Hammel P; Lerch MM; Mayerle J; Tjaden C; Strobel O; Hackert T; Büchler MW; Neoptolemos JP; JAMA Surg; 2019 Nov; 154(11):1038-1048. PubMed ID: 31483448 [TBL] [Abstract][Full Text] [Related]